Gabapentin Capsule
Product Images NDC 43063-673

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 43063-673). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063673 (43063673)

Gabapentin USP 300 mg capsules label from PD-Rx Pharmaceuticals, Inc. The label states it contains 45 capsules and includes warnings about drowsiness, avoiding alcohol, and not taking antacids simultaneously. It shows the NDC 43063-673-45, lot number C22B13, and expiration date 03/2024. Directions for dosage frequency are printed but left blank to be filled by a healthcare provider.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A formula for calculating creatinine clearance (CLCr) based on age, weight, and serum creatinine, with an adjustment factor for female patients. The formula includes elements: 140 minus age (years), multiplied by weight (kg), divided by 72 times serum creatinine (mg/dL), and multiplied by 0.85 for females.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin consistently shows lower pain scores than placebo throughout the study.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph showing mean pain scores over a 7-week period comparing placebo and two dosages of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks, and the y-axis represents mean pain scores, with data divided into a 3-week dose titration period and a 4-week fixed dose period. Gabapentin groups show a decline in pain scores compared to placebo over time.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing response rates in two studies. Study 1 shows 12% response for placebo (PBO) and 29% for Gabapentin 3600 mg (GBP 3600). Study 2 shows 14% for placebo, 32% for Gabapentin 1800 mg, and 34% for Gabapentin 2400 mg. Statistical significance levels are indicated (p < 0.01, p < 0.001).*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot showing percentage difference versus daily dose (mg) with data points from three studies labeled as Study a, Study b, and Study c. The x-axis indicates daily dose in milligrams, ranging from 600 to 1800 mg, and the y-axis represents percentage difference ranging from 2% to 22%. Each study is represented by distinct markers and labels at various dose levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.